Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial	B-cell chronic lymphocytic leukemia, Blood Protein Disorders, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 3	2025-10-03		NCT05556720

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Monash University	75
University of Melbourne	71
University of Sydney	73

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Alfred Health	Melbourne	Australia	32
Austin Hospital	Heidelberg	Australia	37
Monash Medical Centre	Clayton	Australia	60
Peter MacCallum Cancer Centre	Melbourne	Australia	149
Prince of Wales Hospital	Randwick	Australia	34
Princess Alexandra Hospital	Woolloongabba	Australia	106
Royal Adelaide Hospital	Adelaide	Australia	132
Royal Brisbane and Womens Hospital	Herston	Australia	7
Royal Melbourne Hospital	Melbourne	Australia	2
St Vincents Hospital	Fitzroy	Australia	1
St Vincents Hospital	Darlinghurst	Australia	1
University Geelong Hospital	Geelong	Australia	1
Westmead Hospital	Westmead	Australia	128